NURO - NeuroMetrix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0800
-0.0100 (-0.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.0900
Open2.1000
Bid2.0900 x 1000
Ask2.1000 x 1000
Day's Range2.0200 - 2.1300
52 Week Range0.8100 - 70.0000
Volume211,305
Avg. Volume1,109,877
Market Cap6.69M
Beta (5Y Monthly)2.61
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 28, 2007
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    NeuroMetrix Reports Q1 2020 Financial Results

    WOBURN, Mass., April 23, 2020 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2020.  The Company is a.

  • ACCESSWIRE

    NeuroMetrix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 23, 2020 / NeuroMetrix, Inc. (NASDAQ:NURO) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on April 23, 2020 at 8:00 AM ...

  • GlobeNewswire

    NeuroMetrix Reports Quell® Technology to be Used in NIH-Funded Trial Evaluating Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for Fibromyalgia

    NeuroMetrix, Inc. (NURO) today announced that Quell technology has been selected for use in a large, NIH-funded, randomized, pragmatic clinical trial of TENS for fibromyalgia. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep and mood disturbances. Although several drugs are approved for treating fibromyalgia pain, there is an unmet need for safe, non-pharmacological options.

  • GlobeNewswire

    NeuroMetrix, Inc. Announces Date for First Quarter 2020 Financial Results Conference Call

    NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2020 first quarter financial results before the opening of the market on Thursday, April 23, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on April 23, 2020 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 6528139.

  • GlobeNewswire

    NeuroMetrix Announces 2020 Annual Meeting of Shareholders Will Be Held in Virtual Meeting Format Only

    NeuroMetrix, Inc. (NURO) today announced that, due to the public health impact of the COVID-19 pandemic and in accordance with orders issued by the Governor of the Commonwealth of Massachusetts, the Company’s 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held in a virtual meeting format only. The link to the virtual meeting is http://viewproxy.com/neurometrix/2020/vm. As described in the proxy materials for the Annual Meeting previously distributed, you are entitled to participate in the Annual Meeting if you were a shareholder as of the close of business on March 2, 2020, the record date, or hold a legal proxy for the meeting provided by your bank, broker, or nominee.

  • GlobeNewswire

    NeuroMetrix Provides Quell® Technology Commercial Strategy and Pipeline Update

    NeuroMetrix, Inc. (NURO) today provided an update on its Quell technology commercial strategy and pipeline. An estimated 100 million US adults have chronic pain. People with chronic pain may also have low quality sleep, anxiety, depression, and poor overall health.

  • GlobeNewswire

    NeuroMetrix Reports Clinical Studies Recently Published on DPNCheck®

    WOBURN, Mass., March 05, 2020 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the recent publication of three additional DPNCheck clinical studies. DPNCheck is a.

  • GlobeNewswire

    NeuroMetrix Reports Scientific Presentations at the American Academy of Pain Medicine 2020 Annual Meeting

    WOBURN, Mass., Feb. 25, 2020 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the American Academy of Pain Medicine (AAPM) 36th.

  • GlobeNewswire

    NeuroMetrix Reports Q4 and Full Year 2019 Financial Results

    WOBURN, Mass., Jan. 27, 2020 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2019. The Company.

  • GlobeNewswire

    NeuroMetrix, Inc. 2019 Financial Conference Call Rescheduled to Monday January 27, 2020

    NeuroMetrix, Inc. (NURO) today announced the shift of its 2019 financial conference call to Monday, January 27, 2020 at 8:00am Eastern Time. The Company apologized for any inconvenience this may have caused. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 6728609.

  • GlobeNewswire

    NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2019 Financial Results Conference Call

    NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2019 fourth quarter and full year financial results before the opening of the market on Thursday, January 23, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on January 23, 2020 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 6728609.

  • GlobeNewswire

    NeuroMetrix Announces One-for-Ten Reverse Split

    NeuroMetrix, Inc. (NURO) today announced the effectiveness of a one-for-ten reverse split of its common stock. The shares underlying the Company's outstanding options and warrants will also be adjusted accordingly. The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

  • GlobeNewswire

    NeuroMetrix Reports Q3 2019 Financial Results

    WOBURN, Mass., Oct. 17, 2019 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2019. The Company.

  • GlobeNewswire

    NeuroMetrix Announces Updates to Quell 2.0 Commercial Strategy

    NeuroMetrix, Inc. (NURO), a health technology company that develops and commercializes products for the chronic pain and diabetes markets, today announced important updates to its Quell® 2.0 commercial strategy.  This novel wearable device for the symptomatic relief of chronic pain is central to the Company’s vision of helping people reclaim their lives from chronic pain through neuroscience and technology. The Company is shifting to an exclusively direct-to-consumer model delivered via the QuellRelief.com website, that will allow it to offer the innovative Quell 2.0 system at accessible price points.  This streamlined distribution model will allow more people with chronic pain to benefit from the advanced Quell pain relief technology.  The new approach will also open the door for more people to take advantage of electrode savings through a subscription service.

  • GlobeNewswire

    NeuroMetrix, Inc. Announces Date for Third Quarter 2019 Financial Results Conference Call

    NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2019 third quarter financial results before the opening of the market on Thursday, October 17, 2019. The Company will host a conference call at 8:00 a.m., Eastern Time on October 17, 2019 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 3999665.

  • GlobeNewswire

    NeuroMetrix Reports Q2 2019 Financial Results

    WALTHAM, Mass., July 18, 2019 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2019. The Company develops.

  • GlobeNewswire

    NeuroMetrix, Inc. Announces Date for Second Quarter 2019 Financial Results Conference Call

    NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2019 second quarter financial results before the opening of the market on Thursday, July 18, 2019. The Company will host a conference call at 8:00 a.m., Eastern Time on July 18, 2019 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 7357689.

  • GlobeNewswire

    NeuroMetrix Provides Strategic Update

    NeuroMetrix, Inc. (NURO), a health technology company addressing chronic health conditions including chronic pain, sleep disorders and diabetes, today reported on its strategy of optimizing its commercial products while reducing operating costs and preserving cash. The Company is focused on supporting its DPNCheck® product line, managing its existing Quell® business while evaluating alternative therapeutic applications for the core technology, maintaining its strategic collaboration with GlaxoSmithKline, and attempting to negotiate a settlement of the previously disclosed and ongoing Federal Trade Commission (FTC) investigation which is centered on Quell advertising. In its efforts to preserve cash, the Company has implemented a reduction in force affecting 11 employees, all of whom have ceased employment with the Company.